B-Cell Depletion for Autoimmune Rheumatic Diseases: Expert Perspectives of This Mechanistic Therapeutic Approach in Clinical Context
PeerVoice
1 views
47 slides
Oct 08, 2025
Slide 1 of 47
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
About This Presentation
Thomas Dörner, MD, Nancy Carteron, MD, FACR, and Manuel F. Ugarte-Gil, MD, MSc, PhD, discuss autoimmune rheumatic diseases in this IME activity titled "B-Cell Depletion for Autoimmune Rheumatic Diseases: Expert Perspectives of This Mechanistic Therapeutic Approach in Clinical Context." Fo...
Slide Content
PeerVoice
B-Cell Depletion for Autoimmune Rheumatic Diseases: Expert Perspectives of
This Mechanistic Therapeutic Approach in Clinical Context
Learning Objectives
Explain the impact of suboptimal treatment of autoimmune rheumatic diseases on
patient outcomes
Discuss the mechanistic role of B cells in the pathophysiology of
autoimmune rheumatic diseases
Explain why—despite suboptimal results with established B-cell-targeting therapies in
autoimmune rheumatic diseases such as Sjógren's disease, systemic lupus
erythematosus (SLE), and lupus nephritis—B-cell-targeting still holds therapeutic
promise
Identify B-cell-targeting therapies currently being investigated for
autoimmune rheumatic diseases and their methods for achieving B-cell depletion
This independent medical education activity is supported by an educational grant from Novartis Pharma AG
www.peervoice.com/SDS870 Copyright © 2010-2025, Pe
B-Cell Depletion for Autoimmune Rheumatic Diseases: Expert Perspectives of
This Mechanistic Therapeutic Approach in Clinical Context
Learning Objectives
Explain the impact of suboptimal treatment of autoimmune rheumatic diseases on
patient outcomes
Discuss the mechanistic role of B cells in the pathophysiology of
autoimmune rheumatic diseases
Explain why—despite suboptimal results with established B-cell-targeting therapies in
autoimmune rheumatic diseases such as Sjógren's disease, systemic lupus
erythematosus (SLE), and lupus nephritis—B-cell-targeting still holds therapeutic
promise
Identify B-cell-targeting therapies currently being investigated for
autoimmune rheumatic diseases and their methods for achieving B-cell depletion
This independent medical education activity is supported by an educational grant from Novartis Pharma AG
www.peervoice.com/SDS870 Copyright © 2010-2025, Pe
PeerVoice
Part 1 of 3: Common Challenges and Trends in the Treatment of
Autoimmune Rheumatic Diseases
Nt po!
a
Thomas Dórner, MD Nancy Carteron, MD, FACR Manuel F. Ugarte-Gil, MD, MSc, PhD
Charite Berlin and DRFZ Berlin University of California, Universidad Cientifica del Sur
Charite Universitátsmedizin Berlin Berkeley and San Francisco Hospital Guillermo Almenara Irigoyen EsSalud
Berlin, Germany Interdisciplinary Sjógren's Clinic Lima, Perú
Berkeley, California, USA
Copyright © 2010-2025, PeerVoice
Part 1 of 3: Common Challenges and Trends in the Treatment of
Autoimmune Rheumatic Diseases
Nt po!
a
Thomas Dórner, MD Nancy Carteron, MD, FACR Manuel F. Ugarte-Gil, MD, MSc, PhD
Charite Berlin and DRFZ Berlin University of California, Universidad Cientifica del Sur
Charite Universitátsmedizin Berlin Berkeley and San Francisco Hospital Guillermo Almenara Irigoyen EsSalud
Berlin, Germany Interdisciplinary Sjógren's Clinic Lima, Perú
Berkeley, California, USA
Copyright © 2010-2025, PeerVoice
PeerVoice
Thomas Dérner, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AbelZeta Inc; Bristol Myers Squibb Company; F. Hoffmann-La Roche Ltd;
Johnson & Johnson; and Novartis AG.
Honoraria from AbelZeta Inc; Bristol Myers Squibb Company; F. Hoffmann-La Roche
Ltd; Johnson & Johnson; Novartis AG; and UCB Pharma Ltd.
Nancy Carteron, MD, FACR, has a financial interest/relationship or affiliation in
the form of:
Consultant for Bristol Myers Squibb Company.
Manuel F. Ugarte-Gil, MD, MSc, PhD, has a financial interest/relationship or affiliation in
the form of:
Consultant for AstraZeneca; Grupo Ferrer Internacional, S.A; GSK plc.; and Tecnofarma.
Grant/Research Support from Janssen Inc.
Speakers Bureau participant with AstraZeneca.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
Thomas Dérner, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AbelZeta Inc; Bristol Myers Squibb Company; F. Hoffmann-La Roche Ltd;
Johnson & Johnson; and Novartis AG.
Honoraria from AbelZeta Inc; Bristol Myers Squibb Company; F. Hoffmann-La Roche
Ltd; Johnson & Johnson; Novartis AG; and UCB Pharma Ltd.
Nancy Carteron, MD, FACR, has a financial interest/relationship or affiliation in
the form of:
Consultant for Bristol Myers Squibb Company.
Manuel F. Ugarte-Gil, MD, MSc, PhD, has a financial interest/relationship or affiliation in
the form of:
Consultant for AstraZeneca; Grupo Ferrer Internacional, S.A; GSK plc.; and Tecnofarma.
Grant/Research Support from Janssen Inc.
Speakers Bureau participant with AstraZeneca.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
Case: Maria
» 45-year-old female diagnosed with SLE age 22
+ Presenting symptoms: Oral ulcers, fatigue,
arthralgia, membranous GN
+ Therapy: mycophenolate + hydroxychloroquine (HC);
remission on HC alone
GN: glomerulonephriti: SLE: systemic lupus erythematosus,
Courtesy of Nancy Carteron, MD, FACR; April 2025,
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
Case: Maria
» 45-year-old female diagnosed with SLE age 22
+ Presenting symptoms: Oral ulcers, fatigue,
arthralgia, membranous GN
+ Therapy: mycophenolate + hydroxychloroquine (HC);
remission on HC alone
GN: glomerulonephriti: SLE: systemic lupus erythematosus,
Courtesy of Nancy Carteron, MD, FACR; April 2025,
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
Case: Maria (Cont'd)
+ Developed dry eye, dry mouth, new fatigue,
peripheral neuropathy, and ataxic gait
+ WBC 3.0; lymphopenia; hypokalaemia; low C4;
elevated IgG; IgM kappa monoclonal antibody;
AD ESR 50; urinalysis normal
+ SSA+ (Ro52+, Ro60+); SSB+; ANA 1:160 speckled;
RF 40; CCPAb-
+ Family history: Lupus, lymphoma,
autoimmune thyroid
ANA: antinuclear antibody, CCPAL: cai cirulinatedpeptide antibody: ESR: erythrocyte sedimentation rte immunoglobulin RF: heumatoi factor
WAC. white bocd ces,
Courtesy of Nancy Carteron. MD. FACR: Apr 2025
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
Case: Maria (Cont'd)
+ Developed dry eye, dry mouth, new fatigue,
peripheral neuropathy, and ataxic gait
+ WBC 3.0; lymphopenia; hypokalaemia; low C4;
elevated IgG; IgM kappa monoclonal antibody;
AD ESR 50; urinalysis normal
+ SSA+ (Ro52+, Ro60+); SSB+; ANA 1:160 speckled;
RF 40; CCPAb-
+ Family history: Lupus, lymphoma,
autoimmune thyroid
ANA: antinuclear antibody, CCPAL: cai cirulinatedpeptide antibody: ESR: erythrocyte sedimentation rte immunoglobulin RF: heumatoi factor
WAC. white bocd ces,
Courtesy of Nancy Carteron. MD. FACR: Apr 2025
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
Spectrum of Organ/System Involvement in Sjógren's Disease
Dysphagia, 27%
Chronic gastritis, 3.1%
0) Pericarditis, 0.7%
Acute pancreatitis, 06%, topa | ov, 05%
PAH S A JS
CS An YO vanopay.0s%
Pleuritis, 1.6% hs >
. Constitutional, Glandular, Uveitis 0.9%
Sinusitis, 05% (2) Lymph- 10: orbital pseudotumour, 0.2%
Hearing loss, 0.6% ( Episcleritis, 0.6%
_ Small-fibre neuropathy, 0.8%
O) Restless syndrome, 0.6%
Dysautonomy, 0.4%
Panniculitis, 0.2% V7"
Granuloma annulare, 0.2%
Erythema nodosum, 04%
) amyloidosis, 0.2%
‘CHB: congenital heart block: CNS: central nervous system: ESSDAL EULAR Sjogren's Syndrome Disease Activity Index: PA: pulmonary arterial hypertension;
NS: peripheral nervous system.
Retamozo $ et al. Clin Exp Rheumatol. 2019:37( suppl 18)97-106,
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
Spectrum of Organ/System Involvement in Sjógren's Disease
Dysphagia, 27%
Chronic gastritis, 3.1%
0) Pericarditis, 0.7%
Acute pancreatitis, 06%, topa | ov, 05%
PAH S A JS
CS An YO vanopay.0s%
Pleuritis, 1.6% hs >
. Constitutional, Glandular, Uveitis 0.9%
Sinusitis, 05% (2) Lymph- 10: orbital pseudotumour, 0.2%
Hearing loss, 0.6% ( Episcleritis, 0.6%
_ Small-fibre neuropathy, 0.8%
O) Restless syndrome, 0.6%
Dysautonomy, 0.4%
Panniculitis, 0.2% V7"
Granuloma annulare, 0.2%
Erythema nodosum, 04%
) amyloidosis, 0.2%
‘CHB: congenital heart block: CNS: central nervous system: ESSDAL EULAR Sjogren's Syndrome Disease Activity Index: PA: pulmonary arterial hypertension;
NS: peripheral nervous system.
Retamozo $ et al. Clin Exp Rheumatol. 2019:37( suppl 18)97-106,
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
Disease Burden in Sjógren's Disease
Considerable impact on day-to-day life
Decreased quality of life similar to patients with RA and SLE
Increased risk of disabi
ased mortality in a subset of patients with Sjogren's disease
RA: rheumatoid arthritis.
Barrio-Cortes J et al Clin Exp Rheumatol. 2023;412387-240. Miyamoto ST et al Rheumatology (Oxford). 2021:60:2588-2601
Huang H et al Rheumatology (Oxtord). 202160:4029-4038.
www.peervoi
om/SDS870 Copyright © 2010-2025, PeerVoice
Disease Burden in Sjógren's Disease
Considerable impact on day-to-day life
Decreased quality of life similar to patients with RA and SLE
Increased risk of disabi
ased mortality in a subset of patients with Sjogren's disease
RA: rheumatoid arthritis.
Barrio-Cortes J et al Clin Exp Rheumatol. 2023;412387-240. Miyamoto ST et al Rheumatology (Oxford). 2021:60:2588-2601
Huang H et al Rheumatology (Oxtord). 202160:4029-4038.
www.peervoi
om/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
Sjogren's Disease is NOT Just a Disease of Dryness!
According to the Living With Sjógren's patient survey:
81%:
Significant
emotional burden
80%:
“Brain fog” is
experienced
symptom
21 symptoms experienced by >50%
36 symptoms experienced by 230%
H
&
i
commonly E
i
IM
25%:
Fatigue is greatest
negative impact E =
PALIN,
‘The Living with Sjogren's patient survey was conducted by The Harris Poll on behalf of the Sjogren's Foundation. This survey was designed to gain
insight into the variety and severity of what adult US individuals living with Sjogren's experience and how the disease impacts their quality of life.
Courtesy of Nancy Carteron, MD, FACR on behalf of Sjögren’s Foundation.
www.peervoice.com/SDS870 Copyright © 2010-2025,
Sjogren's Disease is NOT Just a Disease of Dryness!
According to the Living With Sjógren's patient survey:
81%:
Significant
emotional burden
80%:
“Brain fog” is
experienced
symptom
21 symptoms experienced by >50%
36 symptoms experienced by 230%
H
&
i
commonly E
i
IM
25%:
Fatigue is greatest
negative impact E =
PALIN,
‘The Living with Sjogren's patient survey was conducted by The Harris Poll on behalf of the Sjogren's Foundation. This survey was designed to gain
insight into the variety and severity of what adult US individuals living with Sjogren's experience and how the disease impacts their quality of life.
Courtesy of Nancy Carteron, MD, FACR on behalf of Sjögren’s Foundation.
www.peervoice.com/SDS870 Copyright © 2010-2025,
PeerVoice
The diagnosis of Sj
other autoimmune disorder:
Advances in biomarker and physiopathology discovery should result in more
sensitive/specific tests and clinical subgroup identification for Sjogren's disease
Courtesy of Nancy Carteron, MD, FACR: April 2025,
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
The diagnosis of Sj
other autoimmune disorder:
Advances in biomarker and physiopathology discovery should result in more
sensitive/specific tests and clinical subgroup identification for Sjogren's disease
Courtesy of Nancy Carteron, MD, FACR: April 2025,
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
Most Common SLE Symptoms: European Survey
100 I Regulariy experienced
m Most bothersome
80
x
§ 60
a
& 40
Data from 4,375 SLE survey respondents from 35 European countries: 95.9% women; median age, 45 (IQR, 36-54) y; 70.7% Caucasians.
Cornet A et al. Lupus Sci Med, 202188000469,
www.peervoice.com/SDS870
Copyright © 2010-2025, PeerVoice
Most Common SLE Symptoms: European Survey
100 I Regulariy experienced
m Most bothersome
80
x
§ 60
a
& 40
Data from 4,375 SLE survey respondents from 35 European countries: 95.9% women; median age, 45 (IQR, 36-54) y; 70.7% Caucasians.
Cornet A et al. Lupus Sci Med, 202188000469,
www.peervoice.com/SDS870
Copyright © 2010-2025, PeerVoice
PeerVoice
Reported SLE Treatments: European Survey
100 Other Treatments
80 | 750
x
ei 684
5
pS 52.4 50.1
É 308
3 40 32.9 29.7
5 25% o,
. 170
¿20 | 1 109 | nr
5g 5.
a 4 m2 A | |
EF » æ «© ¢ © ¢ g €
E FR ER EEE $ E ¿ES $ és #
SES LE ESESE EF EE SRE
Data from 4,375 SLE survey respondents from 35 European countries: 95.9% women; median age, 45 (IQR, 36-54) y; 70.7% Caucasians.
Graph results shown: n = 4,099; oral steroid dose available: n = 3,978.
NSAIDs: nonsteroidal anti-inflammatory drugs.
Cornet A et al. Lupus Sci Med. 20248:e000469,
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
Reported SLE Treatments: European Survey
100 Other Treatments
80 | 750
x
ei 684
5
pS 52.4 50.1
É 308
3 40 32.9 29.7
5 25% o,
. 170
¿20 | 1 109 | nr
5g 5.
a 4 m2 A | |
EF » æ «© ¢ © ¢ g €
E FR ER EEE $ E ¿ES $ és #
SES LE ESESE EF EE SRE
Data from 4,375 SLE survey respondents from 35 European countries: 95.9% women; median age, 45 (IQR, 36-54) y; 70.7% Caucasians.
Graph results shown: n = 4,099; oral steroid dose available: n = 3,978.
NSAIDs: nonsteroidal anti-inflammatory drugs.
Cornet A et al. Lupus Sci Med. 20248:e000469,
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
Reported SLE Symptoms/Treatments: Latin American Survey
Most commonly
affected organs:
Joints (68.1%)
Skin (47.3%)
Kidney (35.6%)
30%:
Problems
accessing
consultation/
treatment
Reported Treatments, %
40 356
x N
FE ES &
PS CL Se
S Se
e oS
ES
é*
€
Data from 2139 SLE survey respondents from 13 countries in Latin America: 95.9% female;
‘median age, 38 (IQR, 31-46). Mean dose of steroids: 5 mg/d.
Fernandez D et al Pan-American League of Rheumatology Congress 2025 (PANLAR 2025). Poster 1049,
www.peervoice.com/SDS870
54
pS
=
E
$
Sy
Copyright © 2010-2025, PeerVoice
Reported SLE Symptoms/Treatments: Latin American Survey
Most commonly
affected organs:
Joints (68.1%)
Skin (47.3%)
Kidney (35.6%)
30%:
Problems
accessing
consultation/
treatment
Reported Treatments, %
40 356
x N
FE ES &
PS CL Se
S Se
e oS
ES
é*
€
Data from 2139 SLE survey respondents from 13 countries in Latin America: 95.9% female;
‘median age, 38 (IQR, 31-46). Mean dose of steroids: 5 mg/d.
Fernandez D et al Pan-American League of Rheumatology Congress 2025 (PANLAR 2025). Poster 1049,
www.peervoice.com/SDS870
54
pS
=
E
$
Sy
Copyright © 2010-2025, PeerVoice
PeerVoice
Medication Use Among Patients With Sjogren's Disease
mEver Used Currently Used
Eye Drops, Artificial Tears/Ointmont (Non-Rs)|
Rx Eye Drops]
Tear Duct SurgeryIPugs
‘Adjunctive Dry Eye Therapy
Ansibitic Eye Ointment
‘Autologous Eye Serum
‘Oral Comfort Agents
Fluoride
Chorhericine Rinse/Non-Fluorid Romineraising
‘OMARDS
Injectabioinfusible Biologics |
Stecoid injections
Hoaïth Food Supplements Remedies
vitamin D|
Thyroid Mediation
Antdeprossents
Sjögren's Foundation Rx Pain Kilors
survey demographics (N = 2,961). Here Pin Mac or
DMARD: disease-modifying antirheumatic drug: Rx prescription.
McCoy SS et al Clin Rheumatol. 2022;812071-2078,
www.peervoice.com/SDS870 Copyright © 2010-2025, Peer
Medication Use Among Patients With Sjogren's Disease
mEver Used Currently Used
Eye Drops, Artificial Tears/Ointmont (Non-Rs)|
Rx Eye Drops]
Tear Duct SurgeryIPugs
‘Adjunctive Dry Eye Therapy
Ansibitic Eye Ointment
‘Autologous Eye Serum
‘Oral Comfort Agents
Fluoride
Chorhericine Rinse/Non-Fluorid Romineraising
‘OMARDS
Injectabioinfusible Biologics |
Stecoid injections
Hoaïth Food Supplements Remedies
vitamin D|
Thyroid Mediation
Antdeprossents
Sjögren's Foundation Rx Pain Kilors
survey demographics (N = 2,961). Here Pin Mac or
DMARD: disease-modifying antirheumatic drug: Rx prescription.
McCoy SS et al Clin Rheumatol. 2022;812071-2078,
www.peervoice.com/SDS870 Copyright © 2010-2025, Peer
PeerVoice
Key Challenges in Latin America
Challenge
Delayed diagnosis and healthcare access
issues
Sjógren's Disease
Lower awareness and lack of standard
diagnostic criteria contribute to delayed
diagnoses
SLE
525% of patients receive a misdiagnosis
before correct diagnosis; rheumatologist
shortages cause delays
imited access to treatments
Limited access to immunosuppressants
and biological therapies hinders effective
treatment
‘Only 35% of patients in Latin America have
access to specialised treatments; limited
availability of biologics
Higher disease severity in Mestizo and,
‘Amerindian populations
Ethnic variations impact disease
presentation; limited data on outcomes for
Mestizo populations
Mestizo and Amerindian patients have
higher rates of LN and poorer long-term.
‘outcomes
Economic and social barriers to disease
management
‘Socioeconomic disparities affect disease
management, leading to lower treatment
adherence
20% of patients had to stop working due
to SLE; insurance and medication access
issues
imited awareness and diagnostic
challenges
Many cases remain undiagnosed due to
the overlap of symptoms with other
‘autoimmune diseases
Lack of knowledge among primary care
physicians leads to underdiagnosis and
delayed referral
High burden of systemic symptoms and
comorbidities
Higher prevalence of dryness, fatigue, and
polyautoimmunity impacts quality of life
“and function
Fatigue and joint pain significantly impact
daily life; high steroid dependence
increases long-term damage
LN: lupus nep
Elera-Fitzcarraïd C et al. Expert Opin Pharmacother. 2025:251-12. Fernandez D et al. PANLAR 2025. Poster 1049. Restrepo-Jiménez P et al. Joint Bone Spine.
2019:86:620-626. Ugarte-Gil MF, Alarcón GS. Clin Immunol Communications. 2023:460-64,
www.peervoice.com/SDS870
Copyright © 2010-2025, PeerVoice
Key Challenges in Latin America
Challenge
Delayed diagnosis and healthcare access
issues
Sjógren's Disease
Lower awareness and lack of standard
diagnostic criteria contribute to delayed
diagnoses
SLE
525% of patients receive a misdiagnosis
before correct diagnosis; rheumatologist
shortages cause delays
imited access to treatments
Limited access to immunosuppressants
and biological therapies hinders effective
treatment
‘Only 35% of patients in Latin America have
access to specialised treatments; limited
availability of biologics
Higher disease severity in Mestizo and,
‘Amerindian populations
Ethnic variations impact disease
presentation; limited data on outcomes for
Mestizo populations
Mestizo and Amerindian patients have
higher rates of LN and poorer long-term.
‘outcomes
Economic and social barriers to disease
management
‘Socioeconomic disparities affect disease
management, leading to lower treatment
adherence
20% of patients had to stop working due
to SLE; insurance and medication access
issues
imited awareness and diagnostic
challenges
Many cases remain undiagnosed due to
the overlap of symptoms with other
‘autoimmune diseases
Lack of knowledge among primary care
physicians leads to underdiagnosis and
delayed referral
High burden of systemic symptoms and
comorbidities
Higher prevalence of dryness, fatigue, and
polyautoimmunity impacts quality of life
“and function
Fatigue and joint pain significantly impact
daily life; high steroid dependence
increases long-term damage
LN: lupus nep
Elera-Fitzcarraïd C et al. Expert Opin Pharmacother. 2025:251-12. Fernandez D et al. PANLAR 2025. Poster 1049. Restrepo-Jiménez P et al. Joint Bone Spine.
2019:86:620-626. Ugarte-Gil MF, Alarcón GS. Clin Immunol Communications. 2023:460-64,
www.peervoice.com/SDS870
Copyright © 2010-2025, PeerVoice
PeerVoice
Unmet Needs and Barriers in Sjogren's Disease and SLE
—
+ Lack of effective DMTs + Persistent disease activity and
* Clinical heterogeneity and frequent flares
patient stratification + GC treatment dependency and
+ Improved diagnostic tools toxicity
+ Patient-reported outcome + High comorbidity burden
measures + Healthcare disparities and
treatment
+ Implementation of treat-to-
target strategy and damage
+ Long-term survival
DMT: disease-modifying therapy; GC: glucocorticoid steroid (also known as CS).
Arnaud, Tektonidou MG. Rheumatology. 2020:58v29-v38. Romo VC et al. RMD Open. 2018:4:2000789,
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
Unmet Needs and Barriers in Sjogren's Disease and SLE
—
+ Lack of effective DMTs + Persistent disease activity and
* Clinical heterogeneity and frequent flares
patient stratification + GC treatment dependency and
+ Improved diagnostic tools toxicity
+ Patient-reported outcome + High comorbidity burden
measures + Healthcare disparities and
treatment
+ Implementation of treat-to-
target strategy and damage
+ Long-term survival
DMT: disease-modifying therapy; GC: glucocorticoid steroid (also known as CS).
Arnaud, Tektonidou MG. Rheumatology. 2020:58v29-v38. Romo VC et al. RMD Open. 2018:4:2000789,
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
Addressing Unmet Needs in Sjógren's Disease
Lack of Effective
DMTs
RCTs underway
targeting:
+ Interferon
signalling and other
cytokines
B cells
T-cell and/or B-cell
costimulation
Antibody
presentation
Clinical Heterogeneity
and Patient Stratification
Use endotypic biomarkers
to stratify patients by:
Pathophysiology
‘Autoantibodies
specificity
Cytokine and/or
molecular profiling
Improved Diagnostic
Novel insights into
clinical, molecular, and
histopathologic
stratification based on:
Multiomics techniques
Emerging imaging
biomarkers
New composite
outcome measures
Patient-Reported
Outcome Measures
The EULAR Sjógren's
Syndrome Disease
Activity Index (ESSDAI)
The EULAR Sjógren's
Syndrome Patient
Reported Index (ESSPRI)
The Sjogren's Syndrome
Responder Index (SSRI)
The Sjôgren's Tool for
Assessing Response
(STAR)
The Composite of
Relevant Endpoints for
Sjógren's Syndrome
(CRESS)
RCT: randomised controlled trial.
Baldini C et al. Nat Rev Rheumatol. 2024:20473-491 Rombo VC et al. RMD Open. 2018:4:2000789,
www.peervoice.com/SDS870
Copyright © 2010-2025, PeerVoice
Addressing Unmet Needs in Sjógren's Disease
Lack of Effective
DMTs
RCTs underway
targeting:
+ Interferon
signalling and other
cytokines
B cells
T-cell and/or B-cell
costimulation
Antibody
presentation
Clinical Heterogeneity
and Patient Stratification
Use endotypic biomarkers
to stratify patients by:
Pathophysiology
‘Autoantibodies
specificity
Cytokine and/or
molecular profiling
Improved Diagnostic
Novel insights into
clinical, molecular, and
histopathologic
stratification based on:
Multiomics techniques
Emerging imaging
biomarkers
New composite
outcome measures
Patient-Reported
Outcome Measures
The EULAR Sjógren's
Syndrome Disease
Activity Index (ESSDAI)
The EULAR Sjógren's
Syndrome Patient
Reported Index (ESSPRI)
The Sjogren's Syndrome
Responder Index (SSRI)
The Sjôgren's Tool for
Assessing Response
(STAR)
The Composite of
Relevant Endpoints for
Sjógren's Syndrome
(CRESS)
RCT: randomised controlled trial.
Baldini C et al. Nat Rev Rheumatol. 2024:20473-491 Rombo VC et al. RMD Open. 2018:4:2000789,
www.peervoice.com/SDS870
Copyright © 2010-2025, PeerVoice
PeerVoice
Addressing Unmet Needs in SLE
Porsistent Disease
Activity and Frequent
Flares
+ Biologic therapies
help reduce disease
activity and flares
Emerging therapies
offer deeper and
more sustained
immunomodulation
GC Treatment
Dependency and
Toxicity
biologic regimens
High Comorbidity
Burden
Early and effective
isease control with
biologics may lower
systemic
inflammation
Healtheare Disparities
‘and Treatment
+ Expansion of
biosimilars and
lower-cost biologics
‘can improve
accessibility
Implementation of
Troat-to-Target
Strategy and Damage
Advanced therapies
‘enable proactive—
rather than
reactive— treatment
‘approaches to
prevent irreversible
‘organ damage
Biomarkers and
real-time disease
monitoring facilitate
‘eerly-intervention
strategies.
Long-Term Survival
Immunomodulatory
therapies and
precision medicine
approaches help.
maintain disease
remission, improving
survival outcomes
Arnaud L, Tektonidou MG. Rheumatology. 2020:59:v29-v38, Dorner T, Lipsky PE. Nat Rev Rheumatol. 2024:20:770-782
Stockfelt M et al Nat Rev Rheumatol. 2025:2111-126.
www.peervoice.com/SDS870
Copyright © 2010-2025, PeerVoice
Addressing Unmet Needs in SLE
Porsistent Disease
Activity and Frequent
Flares
+ Biologic therapies
help reduce disease
activity and flares
Emerging therapies
offer deeper and
more sustained
immunomodulation
GC Treatment
Dependency and
Toxicity
biologic regimens
High Comorbidity
Burden
Early and effective
isease control with
biologics may lower
systemic
inflammation
Healtheare Disparities
‘and Treatment
+ Expansion of
biosimilars and
lower-cost biologics
‘can improve
accessibility
Implementation of
Troat-to-Target
Strategy and Damage
Advanced therapies
‘enable proactive—
rather than
reactive— treatment
‘approaches to
prevent irreversible
‘organ damage
Biomarkers and
real-time disease
monitoring facilitate
‘eerly-intervention
strategies.
Long-Term Survival
Immunomodulatory
therapies and
precision medicine
approaches help.
maintain disease
remission, improving
survival outcomes
Arnaud L, Tektonidou MG. Rheumatology. 2020:59:v29-v38, Dorner T, Lipsky PE. Nat Rev Rheumatol. 2024:20:770-782
Stockfelt M et al Nat Rev Rheumatol. 2025:2111-126.
www.peervoice.com/SDS870
Copyright © 2010-2025, PeerVoice
PeerVoice
Part 2 of 3: Mechanistics Behind Therapeutic Advances in Autoimmune
Rheumatic Diseases: The Rationale for B-Cell Depletion
{
Ni
UE
Thomas Dérner, MD Nancy Carteron, MD, FACR
Charite Berlin and DRFZ Berlin University of California,
Charite Universitätsmedizin Berlin Berkeley and San Francisco
Berlin, Germany Interdisciplinary Sjogren's Clinic
Berkeley, California, USA
Manuel F. Ugarte-Gil, MD, MSc, PhD
Universidad Cientifica del Sur
Hospital Guillermo Almenara Irigoyen EsSalud
Lima, Perú
Copyright © 2010-2025, PeerVoice
Part 2 of 3: Mechanistics Behind Therapeutic Advances in Autoimmune
Rheumatic Diseases: The Rationale for B-Cell Depletion
{
Ni
UE
Thomas Dérner, MD Nancy Carteron, MD, FACR
Charite Berlin and DRFZ Berlin University of California,
Charite Universitätsmedizin Berlin Berkeley and San Francisco
Berlin, Germany Interdisciplinary Sjogren's Clinic
Berkeley, California, USA
Manuel F. Ugarte-Gil, MD, MSc, PhD
Universidad Cientifica del Sur
Hospital Guillermo Almenara Irigoyen EsSalud
Lima, Perú
Copyright © 2010-2025, PeerVoice
PeerVoice
Thomas Dérner, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AbelZeta Inc; Bristol Myers Squibb Company; F. Hoffmann-La Roche Ltd;
Johnson & Johnson; and Novartis AG.
Honoraria from AbelZeta Inc; Bristol Myers Squibb Company; F. Hoffmann-La Roche
Ltd; Johnson & Johnson; Novartis AG; and UCB Pharma Ltd.
Nancy Carteron, MD, FACR, has a financial interest/relationship or affiliation in
the form of:
Consultant for Bristol Myers Squibb Company.
Manuel F. Ugarte-Gil, MD, MSc, PhD, has a financial interest/relationship or affiliation in
the form of:
Consultant for AstraZeneca; Grupo Ferrer Internacional, S.A; GSK plc.; and Tecnofarma.
Grant/Research Support from Janssen Inc.
Speakers Bureau participant with AstraZeneca.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
Thomas Dérner, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AbelZeta Inc; Bristol Myers Squibb Company; F. Hoffmann-La Roche Ltd;
Johnson & Johnson; and Novartis AG.
Honoraria from AbelZeta Inc; Bristol Myers Squibb Company; F. Hoffmann-La Roche
Ltd; Johnson & Johnson; Novartis AG; and UCB Pharma Ltd.
Nancy Carteron, MD, FACR, has a financial interest/relationship or affiliation in
the form of:
Consultant for Bristol Myers Squibb Company.
Manuel F. Ugarte-Gil, MD, MSc, PhD, has a financial interest/relationship or affiliation in
the form of:
Consultant for AstraZeneca; Grupo Ferrer Internacional, S.A; GSK plc.; and Tecnofarma.
Grant/Research Support from Janssen Inc.
Speakers Bureau participant with AstraZeneca.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
Working Model of Immune Activation and Immune Reset
Lymphocyte
Differentiation Immune
£
3
2
E
<
2
z
Overt Disease
Immune
Dysregulation/
‘Autoimmunity
Homeostasis
Lymphocyte Sensitivity to Antigen
i” © mené
Se
Immune 7
Reset
x + Genetic
E Predisposition
tion
Clinical Efficacy
Biomarkers;
Cellular or Molecular
Efficacy Biomarkers
Immune Reset
Biomarkers
Activation
3 7
2
¿a
£ Predisposition
6
3
3
y “Lymphocyte Number
Lymphocyte Number
Junt T etal. Nat Rev Immunol, 2025 Mar 5. dot 10:1038/s41577-025-OlléI-w. Online ahead of print.
www.peervoice.com/SDS870
Copyright © 2010-2025, PeerVoice
Working Model of Immune Activation and Immune Reset
Lymphocyte
Differentiation Immune
£
3
2
E
<
2
z
Overt Disease
Immune
Dysregulation/
‘Autoimmunity
Homeostasis
Lymphocyte Sensitivity to Antigen
i” © mené
Se
Immune 7
Reset
x + Genetic
E Predisposition
tion
Clinical Efficacy
Biomarkers;
Cellular or Molecular
Efficacy Biomarkers
Immune Reset
Biomarkers
Activation
3 7
2
¿a
£ Predisposition
6
3
3
y “Lymphocyte Number
Lymphocyte Number
Junt T etal. Nat Rev Immunol, 2025 Mar 5. dot 10:1038/s41577-025-OlléI-w. Online ahead of print.
www.peervoice.com/SDS870
Copyright © 2010-2025, PeerVoice
PeerVoice
B-Cell Abnormalities in Sjógren's Disease: Predominance of
Peripheral Naive B Cells and Changes in Associated Lymphoma
Patient With Sjogren's Disease Patient With
With Recurrence of NHL Sjógren's Disease
— Plasmablasts
CD27
I— Memory B cells
+ 4} —Naive B cells
CD19
NHL:non-Hodgkin lymphoma.
Hansen A et al Arthritis Rheum. 2002:46:2160-2171
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
B-Cell Abnormalities in Sjógren's Disease: Predominance of
Peripheral Naive B Cells and Changes in Associated Lymphoma
Patient With Sjogren's Disease Patient With
With Recurrence of NHL Sjógren's Disease
— Plasmablasts
CD27
I— Memory B cells
+ 4} —Naive B cells
CD19
NHL:non-Hodgkin lymphoma.
Hansen A et al Arthritis Rheum. 2002:46:2160-2171
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
B-Cell Abnormalities in Active SLE Consistent With
Abnormal Memory
C085
Dorner T et al.J immuno! Methods. 2011363:87-197. Odendahl Met al. J immunol. 2000:166:5970-5979,
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
B-Cell Abnormalities in Active SLE Consistent With
Abnormal Memory
C085
Dorner T et al.J immuno! Methods. 2011363:87-197. Odendahl Met al. J immunol. 2000:166:5970-5979,
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
Increase of Atypical CD1ic+ CD21- B Cells in SLE and pSS
Express Multiple Checkpoint Molecules
sue
= nd a
p13? (4-188) enas
Median CTLAS
Median 0226
*P <.05; *P <.OL ***P «O01; ****P < 0001
CTLA cytotoxic T-lymphocyte-associated protein 4; HD: healthy doners; COS: inducible T-cell costimulatory; pSS: primary Sjogren's syndrome (disease):
PDVPDLE programmed cel death protein programmed cell death igand 1.
Rincon-Arevalo H et al Front Immunol, 202112635615.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
Increase of Atypical CD1ic+ CD21- B Cells in SLE and pSS
Express Multiple Checkpoint Molecules
sue
= nd a
p13? (4-188) enas
Median CTLAS
Median 0226
*P <.05; *P <.OL ***P «O01; ****P < 0001
CTLA cytotoxic T-lymphocyte-associated protein 4; HD: healthy doners; COS: inducible T-cell costimulatory; pSS: primary Sjogren's syndrome (disease):
PDVPDLE programmed cel death protein programmed cell death igand 1.
Rincon-Arevalo H et al Front Immunol, 202112635615.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
Marker Expression and Differentiation of B Cells
‘SLE: J Immunol 2003, Front
Immunol 2019, Arth
Rheumatol 2013, J Cell
Commun Signal 2016, Arth
Rheumatol 2016/2022
RBD/S-1/SARS-Cov2:
Sci Immuno! 2021, Nat Comm
“are 2021 JASN 2021 Front
Immunol 2022, Arthritis
Rheumatol 2022, JCI 2022,
Nat Comm 2024
Tetanus: Blood 2005, Nat
Biotechnol 2013, J Immuno!
2014, PNAS 2014, Blood 2015,
Nat Immunol 2015, Nat
Signatures of: Comm 2024
+ Role of T-cell help KLH: J Immunol 2018
+ Inducing (auto)antigen Diphtheria: Arthritis
+ Immune activation site te Rheumatol 2017
Junt T etal. Nat Rev Immunol. 2025 Mar 5. dot 10.1038/541577-025-O114I-w. Online ahead of print.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
Marker Expression and Differentiation of B Cells
‘SLE: J Immunol 2003, Front
Immunol 2019, Arth
Rheumatol 2013, J Cell
Commun Signal 2016, Arth
Rheumatol 2016/2022
RBD/S-1/SARS-Cov2:
Sci Immuno! 2021, Nat Comm
“are 2021 JASN 2021 Front
Immunol 2022, Arthritis
Rheumatol 2022, JCI 2022,
Nat Comm 2024
Tetanus: Blood 2005, Nat
Biotechnol 2013, J Immuno!
2014, PNAS 2014, Blood 2015,
Nat Immunol 2015, Nat
Signatures of: Comm 2024
+ Role of T-cell help KLH: J Immunol 2018
+ Inducing (auto)antigen Diphtheria: Arthritis
+ Immune activation site te Rheumatol 2017
Junt T etal. Nat Rev Immunol. 2025 Mar 5. dot 10.1038/541577-025-O114I-w. Online ahead of print.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
B Cells in the Pathogenesis of Sjógren's Disease
aes S| sis
Tissue TENS
en @ BAFF
A CXCLIZ
Innate De da
a war
immunity Cytotoxic granules
activation
iar
Y
ELA vr
Near
PA £04
1,17 differentiation
BAFF: 8 cell-activating factor; EFG: efgartigimod alfa; IFN: interferon:
plasma colt R: receptor; SGEC: salivary gland epithelial coll TCZ: to
dendritic cell PC:
: tocilizumab; Tr: folicular helper cell; TIB: tibuizumab.
Baldini C et al. Nat Rev Rheumatol, 2024;20:473-491
www.peervoice.com/SDS870
Copyright © 2010-2025, Peer
B Cells in the Pathogenesis of Sjógren's Disease
aes S| sis
Tissue TENS
en @ BAFF
A CXCLIZ
Innate De da
a war
immunity Cytotoxic granules
activation
iar
Y
ELA vr
Near
PA £04
1,17 differentiation
BAFF: 8 cell-activating factor; EFG: efgartigimod alfa; IFN: interferon:
plasma colt R: receptor; SGEC: salivary gland epithelial coll TCZ: to
dendritic cell PC:
: tocilizumab; Tr: folicular helper cell; TIB: tibuizumab.
Baldini C et al. Nat Rev Rheumatol, 2024;20:473-491
www.peervoice.com/SDS870
Copyright © 2010-2025, Peer
PeerVoice
Memory B Cells, Autoantibody Production, and
Type | IFN Signature
A Positive
Feed-Forward Loop
Memory 8 cll and PC survol
Myeloid)
antigen prgsenting cl
Damaged
cot
DCE
In situ
lymphocytic big
aggregates Ze
in tN mage BnF -enigen
rua immune complexes
ANE anifrolumab; APRIL: a proliferation-inducing ligand DAMP: damage-associated molecular pattern; MHC: major histocompatiblity complex PAMP: pathogen=
associated molecular pattern: RNP: ribonucleoprotein; TCR: T-cell receptor; Ta; T peripheral helper cell Tas tissue-residant memory T coll
Hutloff À et al Arthritis Rheum. 2004:50:3211-3220. Dorner T. Lipsky PE. Not Rev Rheumatol, 2024:20:770-782.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
Memory B Cells, Autoantibody Production, and
Type | IFN Signature
A Positive
Feed-Forward Loop
Memory 8 cll and PC survol
Myeloid)
antigen prgsenting cl
Damaged
cot
DCE
In situ
lymphocytic big
aggregates Ze
in tN mage BnF -enigen
rua immune complexes
ANE anifrolumab; APRIL: a proliferation-inducing ligand DAMP: damage-associated molecular pattern; MHC: major histocompatiblity complex PAMP: pathogen=
associated molecular pattern: RNP: ribonucleoprotein; TCR: T-cell receptor; Ta; T peripheral helper cell Tas tissue-residant memory T coll
Hutloff À et al Arthritis Rheum. 2004:50:3211-3220. Dorner T. Lipsky PE. Not Rev Rheumatol, 2024:20:770-782.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
Dysfunctional Memory B Cells in SLE
B-Cell Signaling in Infection B-Cell Signaling in SLE
ma.
Nucleus
ISRE: IFN-stimulated response element.
Dorner T, Lipsky PE. Nat Rev Rheumatol 2024:20-770-782.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
Dysfunctional Memory B Cells in SLE
B-Cell Signaling in Infection B-Cell Signaling in SLE
ma.
Nucleus
ISRE: IFN-stimulated response element.
Dorner T, Lipsky PE. Nat Rev Rheumatol 2024:20-770-782.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
Marker Expression and Differentiation of B Cells
Activated DN Cell
Plasmablast Short-Lived Long-Lived
Pro-8 Pre-B Transitional Naive Plasma Cell Plasma Cell
©0660
llos
Y BOO
E
BCMA: B-cell maturation antigen: ON: double negative; TACI transmembrane activator and calcium-modulating cyclophilin ligand interactor.
Junt T etal. Nat Rev Immunol. 2025 Mar 5. doi: 10:1038/s41577-025-ONl4I-w. Online ahead of print.
www.peervoice.com/SDS870 Copyright © 2010-2025, Peer
Marker Expression and Differentiation of B Cells
Activated DN Cell
Plasmablast Short-Lived Long-Lived
Pro-8 Pre-B Transitional Naive Plasma Cell Plasma Cell
©0660
llos
Y BOO
E
BCMA: B-cell maturation antigen: ON: double negative; TACI transmembrane activator and calcium-modulating cyclophilin ligand interactor.
Junt T etal. Nat Rev Immunol. 2025 Mar 5. doi: 10:1038/s41577-025-ONl4I-w. Online ahead of print.
www.peervoice.com/SDS870 Copyright © 2010-2025, Peer
PeerVoice
Positioning of Immune Reset and B-Cell Depletion Therapies
Anton EEE
i
3,4
il;
Ed
Hi
=| er =
j
i
ALE: alemtuzumab; BLE blnatumomab; CA(A)R: chimeric autoantibody receptor; HLE-BITE: half-life extended BITE; IAN: ianalumab; INE: inebilizumab; LIN:
linvoseltamab; MOS: mosunetuzumab; OCR: ocrelizumab; OFA: ofatumumab; TEC: tecistamab; UBL: ublituximab.
Junt T etal. Nat Rev Immunol. 2025 Mar 5. dot 10.1038/941577-025-O1I-w. Online ahead of print.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
Positioning of Immune Reset and B-Cell Depletion Therapies
Anton EEE
i
3,4
il;
Ed
Hi
=| er =
j
i
ALE: alemtuzumab; BLE blnatumomab; CA(A)R: chimeric autoantibody receptor; HLE-BITE: half-life extended BITE; IAN: ianalumab; INE: inebilizumab; LIN:
linvoseltamab; MOS: mosunetuzumab; OCR: ocrelizumab; OFA: ofatumumab; TEC: tecistamab; UBL: ublituximab.
Junt T etal. Nat Rev Immunol. 2025 Mar 5. dot 10.1038/941577-025-O1I-w. Online ahead of print.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
Part 3 of 3: What Are We Learning About B-Cell Depletion in the Treatment of
Autoimmune Rheumatic Diseases?
Thomas Dérner, MD Nancy Carteron, MD, FACR Manuel F. Ugarte-Gil, MD, MSc, PhD
Charite Berlin and DRFZ Berlin University of California, Universidad Científica del Sur
Charite Universitátsmedizin Berlin Berkeley and San Francisco Hospital Guillermo Almenara Irigoyen EsSalud
Berlin, Germany Interdisciplinary Sjógren's Clinic Lima, Perú
Berkeley, California, USA
Copyright © 2010-2025, PeerVoice
Part 3 of 3: What Are We Learning About B-Cell Depletion in the Treatment of
Autoimmune Rheumatic Diseases?
Thomas Dérner, MD Nancy Carteron, MD, FACR Manuel F. Ugarte-Gil, MD, MSc, PhD
Charite Berlin and DRFZ Berlin University of California, Universidad Científica del Sur
Charite Universitátsmedizin Berlin Berkeley and San Francisco Hospital Guillermo Almenara Irigoyen EsSalud
Berlin, Germany Interdisciplinary Sjógren's Clinic Lima, Perú
Berkeley, California, USA
Copyright © 2010-2025, PeerVoice
PeerVoice
Thomas Dérner, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AbelZeta Inc; Bristol Myers Squibb Company; F. Hoffmann-La Roche Ltd;
Johnson & Johnson; and Novartis AG.
Honoraria from AbelZeta Inc; Bristol Myers Squibb Company; F. Hoffmann-La Roche
Ltd; Johnson & Johnson; Novartis AG; and UCB Pharma Ltd.
Nancy Carteron, MD, FACR, has a financial interest/relationship or affiliation in
the form of:
Consultant for Bristol Myers Squibb Company.
Manuel F. Ugarte-Gil, MD, MSc, PhD, has a financial interest/relationship or affiliation in
the form of:
Consultant for AstraZeneca; Grupo Ferrer Internacional, S.A; GSK plc.; and Tecnofarma.
Grant/Research Support from Janssen Inc.
Speakers Bureau participant with AstraZeneca.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
Thomas Dérner, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AbelZeta Inc; Bristol Myers Squibb Company; F. Hoffmann-La Roche Ltd;
Johnson & Johnson; and Novartis AG.
Honoraria from AbelZeta Inc; Bristol Myers Squibb Company; F. Hoffmann-La Roche
Ltd; Johnson & Johnson; Novartis AG; and UCB Pharma Ltd.
Nancy Carteron, MD, FACR, has a financial interest/relationship or affiliation in
the form of:
Consultant for Bristol Myers Squibb Company.
Manuel F. Ugarte-Gil, MD, MSc, PhD, has a financial interest/relationship or affiliation in
the form of:
Consultant for AstraZeneca; Grupo Ferrer Internacional, S.A; GSK plc.; and Tecnofarma.
Grant/Research Support from Janssen Inc.
Speakers Bureau participant with AstraZeneca.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
Current Challenges With B-Cell Depletion
Incomplete Depletion _B Cell-Independent Heterogeneous Immunogenicity and
and Relapse Disease Mechanisms Treatment Response Safety Concerns
Residual memory B cells Innate immune
and plasmablasts drive activation
disease recurrence (eg, type | IFN,
monocyte activation)
Post-depletion BAFF sustains disease Some patients
surge promotes even after B-cell experience long
survival of autoreactive depletion remissions; others
B cells, contributing to within months
relapse despite initial
B-cell depletion
RTX trials showed Risk of
inconsistent results
h repeat
pletion cyc
Baldini C et al Nat Rev Rheumatol. 2024:20473-491 Dorner T,Lipsky PE. Nat Rev Rheumatol, 2024;20:770-782.
Stockfelt Met al Nat Rev Rheumatol. 2025:21:1-126.
www.peervoice.com/SDS870 Copyright © 2010-2025, Peer
Current Challenges With B-Cell Depletion
Incomplete Depletion _B Cell-Independent Heterogeneous Immunogenicity and
and Relapse Disease Mechanisms Treatment Response Safety Concerns
Residual memory B cells Innate immune
and plasmablasts drive activation
disease recurrence (eg, type | IFN,
monocyte activation)
Post-depletion BAFF sustains disease Some patients
surge promotes even after B-cell experience long
survival of autoreactive depletion remissions; others
B cells, contributing to within months
relapse despite initial
B-cell depletion
RTX trials showed Risk of
inconsistent results
h repeat
pletion cyc
Baldini C et al Nat Rev Rheumatol. 2024:20473-491 Dorner T,Lipsky PE. Nat Rev Rheumatol, 2024;20:770-782.
Stockfelt Met al Nat Rev Rheumatol. 2025:21:1-126.
www.peervoice.com/SDS870 Copyright © 2010-2025, Peer
PeerVoice
Incomplete Depletion of Tissue-Resident B Lineage Cells Upon
Anti-CD20
ent does not achieve
Biopsy studies show that anti
complete B-cell depletion in tissues
Deli K et al Ann Rheum Dis. 2016:75:1933-1938. Hamza M et al. Ann Rheum Dis. 2012:711881-1887. Kamburova EG et al Am J Transplant. 2013:13:1503-151L
Thurlings RM et al Ann Rheum Dis. 2008:67.917-925.
Copyright © 2010-20:
Incomplete Depletion of Tissue-Resident B Lineage Cells Upon
Anti-CD20
ent does not achieve
Biopsy studies show that anti
complete B-cell depletion in tissues
Deli K et al Ann Rheum Dis. 2016:75:1933-1938. Hamza M et al. Ann Rheum Dis. 2012:711881-1887. Kamburova EG et al Am J Transplant. 2013:13:1503-151L
Thurlings RM et al Ann Rheum Dis. 2008:67.917-925.
Copyright © 2010-20:
PeerVoice
Emergent B Lineage-Depletion Therapies in SLE
Obinutuzumab car Bie lanalumab Darstumumab _ Bortezomib
(om) Teell (AN) (DARA) (Bort)
8
: 9,
E 4 ds
5 £020 Cog or (CDI or
3 ‘BCMA ‘BCMA BAFF-R co38 a
3 E ? ar
2 Fos ¡eme TaN “para
cat cos
= >
gE * Humanised to reduce + Target CDI9 or BCMA, * Fully human to reduce + Spare other B-cell
EE immunogenicity which are more broadly immunogenicity, subsets
ES - Atucosylated Fe expressed compared | * Afucosylated Fe region to
$3 rgion with CD20 improve FCYRI affinity
88 reypuatfinity + Potentilly improved + BAFF-R inhibition
BE. improved direct Gopletion by engagement depletes B cols through
FE cytotoxicity toB cells of Tcells ADOC and simultaneously
é blocks BAFF signaling to
reduce B-cell survival ADCO: antibody-dependent celular cytotoxicity
Stockfelt M et al Nat Rev Rheumatol, 2025;2111-126.
www.peervoice.com/SDS870 Copyright © 2010-2025, Peer
Emergent B Lineage-Depletion Therapies in SLE
Obinutuzumab car Bie lanalumab Darstumumab _ Bortezomib
(om) Teell (AN) (DARA) (Bort)
8
: 9,
E 4 ds
5 £020 Cog or (CDI or
3 ‘BCMA ‘BCMA BAFF-R co38 a
3 E ? ar
2 Fos ¡eme TaN “para
cat cos
= >
gE * Humanised to reduce + Target CDI9 or BCMA, * Fully human to reduce + Spare other B-cell
EE immunogenicity which are more broadly immunogenicity, subsets
ES - Atucosylated Fe expressed compared | * Afucosylated Fe region to
$3 rgion with CD20 improve FCYRI affinity
88 reypuatfinity + Potentilly improved + BAFF-R inhibition
BE. improved direct Gopletion by engagement depletes B cols through
FE cytotoxicity toB cells of Tcells ADOC and simultaneously
é blocks BAFF signaling to
reduce B-cell survival ADCO: antibody-dependent celular cytotoxicity
Stockfelt M et al Nat Rev Rheumatol, 2025;2111-126.
www.peervoice.com/SDS870 Copyright © 2010-2025, Peer
PeerVoice
Novel Agents
Boldini C et al. Nat Rev Rheumatol. 2024;
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
Novel Agents
Boldini C et al. Nat Rev Rheumatol. 2024;
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
Sequential Belimumab and Rituximab in SLE
em amp am
(n=72) (n=144) (n=76)
Absolute Change From Baseline in Absolute Change From Basen
DIS: role con Counts Momory Go20¢6027¢8-CollCounts
i
$
1 ~
= ES EN] y =
ER Ea
Absolute Change From Baseine in Absolute Change From Baselno in
Naive C020: CD Brcailenunts Related COS: O celu
he ES
HE Ha
33 Eso! 22288
pi" = 18 = is = =
Time Since Fest Dota wk Time Since Fret Dota, wc
‘Absolute change from baseline by visit through to week 104 among patients who completed week 52 on treatment (ITT population, N = 292).
‘The data for patients in the BEL/PBO and BEL/RTX groups who re-started belimumab after week 52 and for patients in the BEL/ST group who
withdrew belimumab after week 52 were excluded from the analysis.
IQR: interquartile range; ITT: intention-to-treat; PO: placebo; SLEDAI-2K: SLE Disease Activity Index-2000; ST: standard therapy.
yranow C et al. Ann Rheum Dis. 2024;83:1502-1512.
www.peervoice.com/SDS870
Copyright © 2010-2025, Peer
Sequential Belimumab and Rituximab in SLE
em amp am
(n=72) (n=144) (n=76)
Absolute Change From Baseline in Absolute Change From Basen
DIS: role con Counts Momory Go20¢6027¢8-CollCounts
i
$
1 ~
= ES EN] y =
ER Ea
Absolute Change From Baseine in Absolute Change From Baselno in
Naive C020: CD Brcailenunts Related COS: O celu
he ES
HE Ha
33 Eso! 22288
pi" = 18 = is = =
Time Since Fest Dota wk Time Since Fret Dota, wc
‘Absolute change from baseline by visit through to week 104 among patients who completed week 52 on treatment (ITT population, N = 292).
‘The data for patients in the BEL/PBO and BEL/RTX groups who re-started belimumab after week 52 and for patients in the BEL/ST group who
withdrew belimumab after week 52 were excluded from the analysis.
IQR: interquartile range; ITT: intention-to-treat; PO: placebo; SLEDAI-2K: SLE Disease Activity Index-2000; ST: standard therapy.
yranow C et al. Ann Rheum Dis. 2024;83:1502-1512.
www.peervoice.com/SDS870
Copyright © 2010-2025, Peer
PeerVoice
Sequential Belimumab and Rituximab in SLE (Cont'd)
Primary
isease control! at week 52 167 19.4 255 278 127 (060-271) | 5342
Major Secondary
Clinical remission at week 64 56 63 106 0.69 112 (0.33-3.78) | 8582
Disease controlt at week 104 69 m 23 417 164 (0.57-4.72) | .3613
* mITT population excludes 29 patients from the BEL/ST group due to independent blinded assessors being potentially unblinded.
** ST included CS, antimalarials, immunosuppressants, and NSAIDs. t OR (95% Ci), adjusted treatment difference (95% CI). and P are from logistic
regression model with covariates: Baseline SLEDAI-2K, baseline immunosuppressants, baseline prednisone-equivalent dose, and treatment group.
{Disease control defined as SLEDAI-2K score <2 achieved without immunosuppressants and with a prednisone-equivalent dose of 5 mg/d:
clinical remission defined as clinical SLEDAI-2K score = O, without immunosuppressants, and with CS at a prednisone-equivalent dose of O mg/d.
IBA: independent blinded assessor; mITT: modified ITT.
Aranow C et al. Ann Rheum Dis. 2024;83:1502-1512.
Copyright © 2010-2025, PeerVoice
Sequential Belimumab and Rituximab in SLE (Cont'd)
Primary
isease control! at week 52 167 19.4 255 278 127 (060-271) | 5342
Major Secondary
Clinical remission at week 64 56 63 106 0.69 112 (0.33-3.78) | 8582
Disease controlt at week 104 69 m 23 417 164 (0.57-4.72) | .3613
* mITT population excludes 29 patients from the BEL/ST group due to independent blinded assessors being potentially unblinded.
** ST included CS, antimalarials, immunosuppressants, and NSAIDs. t OR (95% Ci), adjusted treatment difference (95% CI). and P are from logistic
regression model with covariates: Baseline SLEDAI-2K, baseline immunosuppressants, baseline prednisone-equivalent dose, and treatment group.
{Disease control defined as SLEDAI-2K score <2 achieved without immunosuppressants and with a prednisone-equivalent dose of 5 mg/d:
clinical remission defined as clinical SLEDAI-2K score = O, without immunosuppressants, and with CS at a prednisone-equivalent dose of O mg/d.
IBA: independent blinded assessor; mITT: modified ITT.
Aranow C et al. Ann Rheum Dis. 2024;83:1502-1512.
Copyright © 2010-2025, PeerVoice
PeerVoice
lanalumab in Patients With SLE
By vs) Anti-dsDNA Antibody Titres D 1 Complement C3
at e
B-Cell Depletion À E vs di
at28 Weeks 2910 5100
ER 530% ÉS
2 E Bos ES
03 wo $ ET
3 o 7 ES wu Ô “ST a a 6 D mm
BB oo Time on Treatment, wk Time on Treatment, wk
82 so > de i A
1% ds Anti-Ciq Antibody Titres ici Complement C4
a 83. 33,
IAN PRO 35% 28”
ge 2e
3 Jos: 5310.
un SE És
pa oz 3
reo SM TTT a se 8 OT a ee
Time on Treatment, wk Time on Treatment, wk
Interim analysis cutoff 27 July 2022.
‘Shen N et al. American College of Rheumatology (ACR) Convergence 2023. Abstract 2487.
www.peervoice.com/SDS870
Copyright © 2010-2025, Peer
lanalumab in Patients With SLE
By vs) Anti-dsDNA Antibody Titres D 1 Complement C3
at e
B-Cell Depletion À E vs di
at28 Weeks 2910 5100
ER 530% ÉS
2 E Bos ES
03 wo $ ET
3 o 7 ES wu Ô “ST a a 6 D mm
BB oo Time on Treatment, wk Time on Treatment, wk
82 so > de i A
1% ds Anti-Ciq Antibody Titres ici Complement C4
a 83. 33,
IAN PRO 35% 28”
ge 2e
3 Jos: 5310.
un SE És
pa oz 3
reo SM TTT a se 8 OT a ee
Time on Treatment, wk Time on Treatment, wk
Interim analysis cutoff 27 July 2022.
‘Shen N et al. American College of Rheumatology (ACR) Convergence 2023. Abstract 2487.
www.peervoice.com/SDS870
Copyright © 2010-2025, Peer
PeerVoice
lanalumab in Patients With SLE (Cont'd)
SRI-4
Responders
x 80
6 —6— IAN (o = 34)
E gg | So ome) +SRI-4 status
3
E
$ 40 +CS tapered
E
S
= 20
3
$
go
0 4 8 12 16 20 24 28
Treatment Period, wk
Week 28 SRI-4
Interim analysis cutoff: 27 July 2022. Response Endpoint
CS: Predniso(lo)ne or equivalent. Mean, 48.2%
SRI-4: SLE Responder Index-4. (90% Cl, 30.2-64.7)
Shen N et al. ACR Convergence 2023. Abstract 2487.
www.peervoice.com/SDS870
Week 28 Composite
Endpoint
50 16134
40
30
20
10 3/33
o
> ee
Composite Primary Endpoint
Week 28 SRI-4 Response
With Sustained Steroid Reduction
Mean, 34.5% (90% Cl, 19.2-49.4)
Copyright © 2010-2025, PeerVoice
lanalumab in Patients With SLE (Cont'd)
SRI-4
Responders
x 80
6 —6— IAN (o = 34)
E gg | So ome) +SRI-4 status
3
E
$ 40 +CS tapered
E
S
= 20
3
$
go
0 4 8 12 16 20 24 28
Treatment Period, wk
Week 28 SRI-4
Interim analysis cutoff: 27 July 2022. Response Endpoint
CS: Predniso(lo)ne or equivalent. Mean, 48.2%
SRI-4: SLE Responder Index-4. (90% Cl, 30.2-64.7)
Shen N et al. ACR Convergence 2023. Abstract 2487.
www.peervoice.com/SDS870
Week 28 Composite
Endpoint
50 16134
40
30
20
10 3/33
o
> ee
Composite Primary Endpoint
Week 28 SRI-4 Response
With Sustained Steroid Reduction
Mean, 34.5% (90% Cl, 19.2-49.4)
Copyright © 2010-2025, PeerVoice
PeerVoice
Efficacy of CD19 CAR T-Cell Therapy in SLE
Patient Number
Disease
Follow-Up, mo
Drug-Free Remission/No Progression
GC-Free State
No Immunosuppressive Drugs
SLEDAI-2K Anti-dsDNA
25 6000 20
a 5000
2” Sam À 150
fe - 20 2
É 000 À $100
go 5 1909 E
3 600
5 400
MISA 20 À ww ver E
EEES HERE ETTETAMERELTTEDS tZEKLIIEN)
Time, mo
Time, mo Time, mo Time, mo.
Muller F et al.N Engl J Med. 2024:390:687-700.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
Efficacy of CD19 CAR T-Cell Therapy in SLE
Patient Number
Disease
Follow-Up, mo
Drug-Free Remission/No Progression
GC-Free State
No Immunosuppressive Drugs
SLEDAI-2K Anti-dsDNA
25 6000 20
a 5000
2” Sam À 150
fe - 20 2
É 000 À $100
go 5 1909 E
3 600
5 400
MISA 20 À ww ver E
EEES HERE ETTETAMERELTTEDS tZEKLIIEN)
Time, mo
Time, mo Time, mo Time, mo.
Muller F et al.N Engl J Med. 2024:390:687-700.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
Targeting CD38 With Daratumumab Monotherapy for
Refractory Lupus Nephri
“ls
Trend of proteinuria, Cr. C3 and C4 in responder patients at baseline and at 3 months, 6 months and 12 months: n= 5 biological independent samples were used for each
determination (ane por patienttimepoint). Box plots show median and 1st-3rd intorquartdo range, whiskers indicate minimum-maximum. P « 06 was considered significant.
Cr. serum creatinine.
Roccatall D et al. Nat Med. 2023:29:2041-2047.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
Targeting CD38 With Daratumumab Monotherapy for
Refractory Lupus Nephri
“ls
Trend of proteinuria, Cr. C3 and C4 in responder patients at baseline and at 3 months, 6 months and 12 months: n= 5 biological independent samples were used for each
determination (ane por patienttimepoint). Box plots show median and 1st-3rd intorquartdo range, whiskers indicate minimum-maximum. P « 06 was considered significant.
Cr. serum creatinine.
Roccatall D et al. Nat Med. 2023:29:2041-2047.
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVoice
PeerVoice
Obinutuzumab in Active Lupus Nephritis
Adjusted
on PBO
Endpoint (ITT Population) 9 E Difference
(2186) | (en) | een
Primary
Complete renal response at 46.4 331 134
weck 76, % (95% CI) (380-549) | (252-410) | (20-248)
Key Secondary
‘Complete renal response at week 76 427 309 19
with prednisone taper to <7.5 mg/d Gas-su) | (231-387) | (05-292)
between weeks 64-76, % (95% CI)
UPCR « 0.8 at week 76 with no 555 FT] 17 a
intercurrent event, % (95% Ci) (471-640) | (36-502) | (20-254) |
‘Change in eGFR from baseline to 384
week 76, mL/min/173 m? an || E || ences |=
Death or renal-related event through 169 356 168 7
week 76, % (95% Ci) (121-256) | (275-438) | (-274t0 -62)
‘Overall renal response at 591 507 84 7
week 50, % (95% CI) (50.8-67.4) | (422-592) | (-34 to 201)
(Change in FACIT-F score from 14 =
baseline to week 76, points wa SD (-39t012)
www.peervoice.com/SDS870
GR; estimated glomerular fitration rate; FACIT-F: Functional Assessment of Chronic liness Therapy-Fatigue; UPCR urine protein-to-creatinine ratio.
Furie RA et al. N Engl J Med. 2025:3921471-1483,
Copyright © 2010-2025, PeerVoice
Obinutuzumab in Active Lupus Nephritis
Adjusted
on PBO
Endpoint (ITT Population) 9 E Difference
(2186) | (en) | een
Primary
Complete renal response at 46.4 331 134
weck 76, % (95% CI) (380-549) | (252-410) | (20-248)
Key Secondary
‘Complete renal response at week 76 427 309 19
with prednisone taper to <7.5 mg/d Gas-su) | (231-387) | (05-292)
between weeks 64-76, % (95% CI)
UPCR « 0.8 at week 76 with no 555 FT] 17 a
intercurrent event, % (95% Ci) (471-640) | (36-502) | (20-254) |
‘Change in eGFR from baseline to 384
week 76, mL/min/173 m? an || E || ences |=
Death or renal-related event through 169 356 168 7
week 76, % (95% Ci) (121-256) | (275-438) | (-274t0 -62)
‘Overall renal response at 591 507 84 7
week 50, % (95% CI) (50.8-67.4) | (422-592) | (-34 to 201)
(Change in FACIT-F score from 14 =
baseline to week 76, points wa SD (-39t012)
www.peervoice.com/SDS870
GR; estimated glomerular fitration rate; FACIT-F: Functional Assessment of Chronic liness Therapy-Fatigue; UPCR urine protein-to-creatinine ratio.
Furie RA et al. N Engl J Med. 2025:3921471-1483,
Copyright © 2010-2025, PeerVoice
PeerVoice
Sequential Belimumab and Rituximab in Primary
Sjógren's Disease
3%0 y Naive B Cells (CD20+ CD27-)2000
3
sm 8000
gx
e000
Evo
Meco (GR) coli.
0838888885
0588888388
o
0148 12 242836 44.52 68
Total 8 Cells (CDI9+) Memory B Cells (CD20+ CD27+)
— PBO(n=8)
— BEL + RTX (n = 17)
— eet inet)
— RIX(n=16)
A rr raión
014 812 242836 4452 68
TE Tm
014 812 242836 4452 68
Time wk
Plasmablasts (CD27+ CD38+ CD19+)
4000
o
TETERA
tt Timm ft Tent
Mariette X ot al JC! Insight. 20227(23)0168030.
www.peervoice.com/SDS870
Copyright © 2010-2025, PeerVoice
Sequential Belimumab and Rituximab in Primary
Sjógren's Disease
3%0 y Naive B Cells (CD20+ CD27-)2000
3
sm 8000
gx
e000
Evo
Meco (GR) coli.
0838888885
0588888388
o
0148 12 242836 44.52 68
Total 8 Cells (CDI9+) Memory B Cells (CD20+ CD27+)
— PBO(n=8)
— BEL + RTX (n = 17)
— eet inet)
— RIX(n=16)
A rr raión
014 812 242836 4452 68
TE Tm
014 812 242836 4452 68
Time wk
Plasmablasts (CD27+ CD38+ CD19+)
4000
o
TETERA
tt Timm ft Tent
Mariette X ot al JC! Insight. 20227(23)0168030.
www.peervoice.com/SDS870
Copyright © 2010-2025, PeerVoice
PeerVoice
Sequential Belimumab and Rituximab in Primary
Sjôgren's Disease (Cont'd)
MME PEO(n=8) MN BEL+RTX(n=17) MM BEL(n=19) MB RTX (n= 16)
ESSDAI Reduction 23 Points ESSDAI Reduction 25 Points
100 100
80 80
E x
8 so É 60
E 2
8 A
$ 40 2 40
3 &
ES
20 20
o o
Week 24 Week 52 Week 68 Week 24 Week 52 Week 68
ESSDAI reduction vs baseline: completer population N = 60. ESSDAI responder analyses used a generalised estimating equation model
Mariette X et al JCI Insight. 2022:7(23):e163030.
www.peervoice.com/SDS870
Copyright © 2010-2025,
erVeice
Sequential Belimumab and Rituximab in Primary
Sjôgren's Disease (Cont'd)
MME PEO(n=8) MN BEL+RTX(n=17) MM BEL(n=19) MB RTX (n= 16)
ESSDAI Reduction 23 Points ESSDAI Reduction 25 Points
100 100
80 80
E x
8 so É 60
E 2
8 A
$ 40 2 40
3 &
ES
20 20
o o
Week 24 Week 52 Week 68 Week 24 Week 52 Week 68
ESSDAI reduction vs baseline: completer population N = 60. ESSDAI responder analyses used a generalised estimating equation model
Mariette X et al JCI Insight. 2022:7(23):e163030.
www.peervoice.com/SDS870
Copyright © 2010-2025,
erVeice
PeerVoice
lanalumab in Moderate to Severe Primary Sjógren's Disease
Serum AN cores
Concentrations 4 8-CallCounts
we 2
CE is +
2 2 E 200 ,
$, Es
Sole + 8% pa
Ba 5 -00 -000 À
a
cr DO A
A A AS
PBO-Adjusted Change From
Baseline in Serum
RF Concentrations
PBO-Adjusted Change From
Basoline in Serum
IgG Concentrations
Outcomes shown are either a week 24
or to week 24 by treatment group: IAN
concentrations and B-cell counts are
mean (SD). BAFF, RF, and IgG changes
from baseline are LSM (SE).
LSM:loast-squares mean.
Bowman SJ et al Lancet. 2022:398:161-11.
LSM Change in
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVaice
lanalumab in Moderate to Severe Primary Sjógren's Disease
Serum AN cores
Concentrations 4 8-CallCounts
we 2
CE is +
2 2 E 200 ,
$, Es
Sole + 8% pa
Ba 5 -00 -000 À
a
cr DO A
A A AS
PBO-Adjusted Change From
Baseline in Serum
RF Concentrations
PBO-Adjusted Change From
Basoline in Serum
IgG Concentrations
Outcomes shown are either a week 24
or to week 24 by treatment group: IAN
concentrations and B-cell counts are
mean (SD). BAFF, RF, and IgG changes
from baseline are LSM (SE).
LSM:loast-squares mean.
Bowman SJ et al Lancet. 2022:398:161-11.
LSM Change in
www.peervoice.com/SDS870 Copyright © 2010-2025, PeerVaice
PeerVoice
lanalumab in Moderate to Severe Primary Sjógren's Disease
(Cont'd)
ESSDAI Responder Rate at Week 24 ESSDAI Disease Activity at Baseline and Week 24
ESSDAI
100 IAN IAN IAN
89 PBO © Gmg | 50mg 300m;
æ 80 72
E 61 62
A 60 Low 2 o o o
8 Moderate 65 62 67 67
&
z 40 High 33 38 33 33
2
8
u 20
Low 35 48 52 61
© Moderate 50 38 38 Ey
PBO IANSmg IAN 50 IAN 300
mg mg High 15 14 10 2
Bowman SJ et al Lancet. 2022:399161-11
Copyright © 2010-2025, PeerVoice
lanalumab in Moderate to Severe Primary Sjógren's Disease
(Cont'd)
ESSDAI Responder Rate at Week 24 ESSDAI Disease Activity at Baseline and Week 24
ESSDAI
100 IAN IAN IAN
89 PBO © Gmg | 50mg 300m;
æ 80 72
E 61 62
A 60 Low 2 o o o
8 Moderate 65 62 67 67
&
z 40 High 33 38 33 33
2
8
u 20
Low 35 48 52 61
© Moderate 50 38 38 Ey
PBO IANSmg IAN 50 IAN 300
mg mg High 15 14 10 2
Bowman SJ et al Lancet. 2022:399161-11
Copyright © 2010-2025, PeerVoice
PeerVoice
BCMA-Targeted T-Cell-Engager Therapy for
Autoimmune Diseases
E
Primary Sjogren's Disease
PL SG
?
¿a sSopsthic
£ | Intern Mots
E 000
500 15)
o
me | 2 3 2 op
Teclistama Dose, number
Clinical Efficacy Analysis,
Before [After
Patient 3
Idiopathic
Inflammatory
Myositis
VAS Patent Gob) 20/60 | som 50/20 | 60/40
dad Rachen Su core | 30/24 = : =
EST = ET = =
EN = a 278 à
a = = Rens
DAS = = sons | sens
Hea Asset asia | wm eno | sons
2.0088 EVE ETE wary | Tere
Four patients with autoimmune diseases resistant to more than 5 immunosuppressants, including RTX.
Clinical efficacy measures were in units, except VAS (mm) and DLCOSE (% predicted).
CDASI: Cutaneous Dermatomyositis Disease Area and Severity Index: DAS28-CRP: Rheumatoid Arthritis Disease Activity Score with C-reactive protein; DLCOSB:
single-breath diffusion capacity of lung for carbon monoxide; MCV: mutated citrulinated vimentin; MDAS: anti-melanoma differentiation-associated gene 5; MMT-
‘8: Manual Muscle Testing 8: VAS: visual analogue scale,
Hagen M et al.N Eng! J Med. 2024:391:867-869,
www.peervoice.com/SDS870
Copyright © 2010-2025, PeerVoice
BCMA-Targeted T-Cell-Engager Therapy for
Autoimmune Diseases
E
Primary Sjogren's Disease
PL SG
?
¿a sSopsthic
£ | Intern Mots
E 000
500 15)
o
me | 2 3 2 op
Teclistama Dose, number
Clinical Efficacy Analysis,
Before [After
Patient 3
Idiopathic
Inflammatory
Myositis
VAS Patent Gob) 20/60 | som 50/20 | 60/40
dad Rachen Su core | 30/24 = : =
EST = ET = =
EN = a 278 à
a = = Rens
DAS = = sons | sens
Hea Asset asia | wm eno | sons
2.0088 EVE ETE wary | Tere
Four patients with autoimmune diseases resistant to more than 5 immunosuppressants, including RTX.
Clinical efficacy measures were in units, except VAS (mm) and DLCOSE (% predicted).
CDASI: Cutaneous Dermatomyositis Disease Area and Severity Index: DAS28-CRP: Rheumatoid Arthritis Disease Activity Score with C-reactive protein; DLCOSB:
single-breath diffusion capacity of lung for carbon monoxide; MCV: mutated citrulinated vimentin; MDAS: anti-melanoma differentiation-associated gene 5; MMT-
‘8: Manual Muscle Testing 8: VAS: visual analogue scale,
Hagen M et al.N Eng! J Med. 2024:391:867-869,
www.peervoice.com/SDS870
Copyright © 2010-2025, PeerVoice
Tags
autoimmune rheumatic diseases
airds
panlar
pan-american league of associations of rheumatolog
mexico city
ondemand
thomas dörner
nancy carteron
manuel f. ugarte-gil
b-cell–targeting therapy
lupus nephritis
sjogren’s disease
systemic lupus erythematosus
sle
lupus
sjogren’s syndrome
b cells in autoimmune diseases
b cells in autoimmune rheumatic diseases
b cells in airds
ards
Categories
ScienceDownload
Download Slideshow Get the original presentation fileQuick Actions
Statistics
- Views 1
- Slides 47
- Age 76 days
Related Slideshows
23
Earthquakes_Type of Faults_Science G8.pptx
OctabellFabila1
42 views
15
Quiz #1 Science 10 in the first quarter for jhs
HendrixAntonniAmante
41 views
9
Astronomy history from long ago till doday
ssuserbd9abe
41 views
9
Great history of astronomy from long ago till today
ssuserbd9abe
41 views
20
EARTHQUAKE-DRILL.powerpoint.............
chalobrido8
44 views
9
History of astronomy from old times to the present times
ssuserbd9abe
42 views